Low-dose vaginal E2 tablets effectively treat atrophic vaginitis
Twelve weeks of vaginal tablets with either 25 µg or 10 µg estradiol (E2) relieves vaginal symptoms, improves urogenital atrophy, decreases vaginal pH, and increases maturation of the vaginal and urethral epithelium in women with atrophic vaginitis, according to the findings of a multicenter, randomized, double-blind, placebo-controlled trial.
Twelve weeks of vaginal tablets with either 25 µg or 10 µg estradiol (E2) relieves vaginal symptoms, improves urogenital atrophy, decreases vaginal pH, and increases maturation of the vaginal and urethral epithelium in women with atrophic vaginitis, according to the findings of a multicenter, randomized, double-blind, placebo-controlled trial.
The study included 230 postmenopausal women. While improvements were greater with 25 µg than with 10 µg, both doses were effective; efficacy, at least with the 25 µg dose, was maintained to week 52.
Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111:67-76.
Intentional weight loss linked to lower mortality in postmenopausal women
March 11th 2025A recent study shows that intentional weight loss significantly lowers all-cause, cancer, and cardiovascular mortality risks among postmenopausal women, highlighting the importance of targeted weight management.
Read More
